GAZYVA® (obinutuzumab) injection

GAZYVA® (obinutuzumab) injection

Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than rituximab in vitro using human cancer cell lines. Obinutuzumab also demonstrated an increased ability to induce direct cell death when compared to rituximab.